Press Release Archive

10.04.2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

09.19.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

09.14.2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

08.08.2022

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

06.17.2022

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

05.04.2022

Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022

04.28.2022

Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy

04.08.2022

Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

02.14.2022

Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

02.04.2022

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

01.18.2022

Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant

01.12.2022

Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released